Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes fromFinra
Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
- Volatility is at a recent 2 week high. A high volatility of stock movement indicates uncertainty.
|Earning Growth (QoQ)|
|Revenue Growth (QoQ)|
|Held by Institutions %||61%|
|1 Day Vol Adjusted Return||0.4|
|1 Month Vol Adjusted Return||-4.4|
|3 Month Vol Adjusted Return||-6.0|
|6 Month Vol Adjusted Return||-4.4|
|20 Days SMA Price ZScore||-1.5|
|50 Days SMA Price ZScore||-2.1|
|12 -26 Days PPO||-7.2|
|1 Month Average Short Volume Ratio||51.3|
|1 Day Volume Change ZScore||-0.5|
|1 Month Daily Vol||3.7|
The latest analyst coverage could presage a bad day for Y-mAbs Therapeutics, Inc. ( NASDAQ:YMAB ), with the analysts...
NEW YORK, NY / ACCESSWIRE / February 26, 2021 / Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on February 26, 2021 at 9:00 AM Eastern Time.
NEW YORK, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a development-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today reported financial results for 2020. “We are pleased with our 2020 financial results, especially seen in conjunction with the approval of DANYELZA, and the sale of our Priority Review Voucher for $105 m...
Every investor in Y-mAbs Therapeutics, Inc. ( NASDAQ:YMAB ) should be aware of the most powerful shareholder groups...
NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced the closing of its public offering of 2,804,878 shares of its common stock, at a public offering price of $41.00 per share, which includes the exercise in full of the underwriters' option to purchase 3...
NEW YORK, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the fiscal year ended December 31, 2020 on Thursday, February 25, 2021, after the close of the U.S. financial markets. The announcement will be followed by a conference call and webcast with the investment community on Friday, February 26, 2021, at 9 a.m. ET. Participating on the call from Y-mAbs will be Thomas Gad, founder...
Y-mAbs Therapeutics Inc (NASDAQ: YMAB) priced its public offering of 2.4 million common shares at $41 per share, for gross proceeds of approximately $100 million. Underwriters have an option to purchase up to an additional 365,853 shares. The offering is expected to close by February 22. J.P. Morgan, Morgan Stanley, and BofA Securities are acting as the joint book-running managers for the offering. Y-mAbs intends to use the proceeds for commercial infrastructure build-out for launch and other co...